Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.14 -0.28 (-1.04%)
Streaming Delayed Price Updated: 12:16 PM EST, Feb 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented... 
Via Benzinga
Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations
The company is hoping to rival Pfizer's approved treatment for cardiomyopathy. 
Via Investor's Business Daily
2 Incredibly Cheap Growth Stocks to Buy Now
The market has been tougher on these companies than some, but that could be a golden opportunity for the right investor. 
Via The Motley Fool
2 Incredibly Cheap Healthcare Stocks to Buy Now
Top healthcare stocks are a great addition to any portfolio. 
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
A Closer Look at Pfizer's Options Market Dynamics
Via Benzinga
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
Is Pfizer Stock Ready to Bounce Back?
The stock won't stay down forever. 
Via The Motley Fool
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
These underappreciated dividend payers offer yields above 4% at recent prices. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
There's no reason to succumb to gloom and doom here. 
Via The Motley Fool
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
From Pfizer Inc.
Via Business Wire
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season. 
Via Benzinga
Exposures COVID-19
Eli Lilly’s Path to the Next Trillion Market Capitalization
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes. 
Via MarketBeat
Is Pfizer Stock Still a Buy After an Unexpected Setback?
Its long-term growth plan just hit a small bump in the road. 
Via The Motley Fool
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 High-Yielding Stocks
Before interest rates come down, you may want to consider loading up on these terrific income stocks. 
Via The Motley Fool
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,... 
Via Benzinga
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to... 
Via Benzinga
Exposures COVID-19 Product Safety
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
These 3 Stocks Pay You More Than 5% to Own Them
High dividend yields paired with fundamentally sound and undervalued stocks provide opportunities for both income and long-term capital appreciation. 
Via MarketBeat
Mr. Darren Walker, Dr. Albert Bourla, and Secretary General Jens Stoltenberg to be awarded Concordia Leadership Award at the 2024 Annual Summit this September
NEW YORK, N.Y., Aug. 22, 2024 (SEND2PRESS NEWSWIRE) -- The Concordia Leadership Council is proud to announce the recipients of the 2024 Leadership Award: Mr. Darren Walker, President of the Ford... 
Via Send2Press
Value Investing: Unearthing 3 Hidden Gems in Today's Market
Discover undervalued companies and build long-term wealth through the insightful strategy of value investing. 
Via MarketBeat
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
2 Cheap Passive Income Stocks to Buy Now
Passive income stocks offer potential for steady returns and financial security in retirement. 
Via The Motley Fool
3 Top Value Stocks to Buy Right Now
Value stocks offer potential for significant returns in today's overheated market. 
Via The Motley Fool
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Its 12-month relative strength performance is impressive, but Novavax now faces resistance. 
Via Investor's Business Daily
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
Via MarketBeat
Exposures COVID-19 Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19. 
Via The Motley Fool
3 Dividend Stocks to Double Up On Right Now
How does a 5.7% dividend yield sound? 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.